碧参在茶叶行业中的票数：495
【碧参是哪个国家的品牌？】
外推网助力碧参品牌出海！将品牌入驻外推网，定制碧参品牌推广信息，可以显著提高碧参产品曝光，简直是跨境电商爆单神器！目前仅需1000元/年哦~
创建于1996年，集中药材GAP规范化种植/科研/生产/销售于一体的企业
安康北医大制药股份有限公司创建于1996年，2005年经陕西省人民政府批准正式设立为股份制公司，是一家集中药材GAP规范化种植、科研、生产、销售于一体的企业。公司现在员工218人，其中科研技术人员86人，能够独立完成各类新药临床前的全部研究工作，现已投入生产的品种16个，进入新药Ⅲ期临床试验的品种3个，研究开发中的产品12个。
公司注册资本金6536万元，占地面积170亩，建筑面积58660平方米，投资5.76亿元在安康高新技术产业开发区创业东路，按照国家2010版药品GMP规范标准，建成中药原料药及各种提取物、中西药片剂、胶囊剂、颗粒剂、丸剂、软胶囊剂、小输液、小水针、冻干粉针剂、生物制剂等十六条药品GMP现代化生产线。年产绞股蓝总甙（原料药）、葛根素、苦参素、苦参碱（注射用原料药）及其他中药提取物180吨，年产各类中成药及中西药品20亿片、颗、包、支、瓶的生产能力。公司建成的新厂于2014年度投入生产运营，年销售收入以30%的速度增长，现辐射国内30多个省市的销售网络体系已形成。
英文翻译：Founded in 1996, Ankang Beiyida Pharmaceutical Co., Ltd., an enterprise integrating the standardized cultivation / scientific research / production / sales of gap for medicinal materials, was founded in 1996 and formally established as a joint-stock company approved by the people's Government of Shaanxi Province in 2005. It is an enterprise integrating the standardized cultivation, scientific research, production and sales of gap for medicinal materials. The company now has 218 employees, including 86 scientific and technical personnel, who can independently complete all kinds of pre clinical research work of new drugs. There are 16 varieties that have been put into production, 3 varieties that have entered phase III clinical trials of new drugs, and 12 products under research and development. The registered capital of the company is 65.36 million yuan, covering an area of 170 mu, with a building area of 58660 square meters, and an investment of 576 million yuan in Chuangye East Road, Ankang high tech Industrial Development Zone. According to the national GMP standard of 2010 version, the company has completed the construction of traditional Chinese medicine raw materials and various extracts, Chinese and Western tablets, capsules, granules, pills, soft capsules, small infusion, small water needles, freeze-dried powder injections, and raw materials Sixteen modern production lines of GMP, including pharmaceutical preparations. The annual output of total Gypenoside (API), puerarin, matrine, matrine (API for injection) and other extracts of traditional Chinese medicine is 180 tons. The annual output of all kinds of Chinese patent medicine and Chinese and Western medicine is 2 billion tablets, capsules, packages, branches and bottles. The new factory built by the company was put into production and operation in 2014, with an annual sales revenue growth rate of 30%. Now the sales network system radiating over 30 provinces and cities in China has been formed.
本文链接： https://www.waitui.com/brand/763e9c726.html 联系电话：请联系客服添加 联系邮箱：请联系客服添加
浙公网安备 33011802001999号
